RNAZ NASDAQ
Credit Risk of going bust: higher than 91% of companies Debt: 27.0% of company value Bonds: none of note held by US funds details ▾
Total debt $652K against a stock market value of $1.8M.
Distance to default 1.50 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $652K (short-term plus half of long-term), stock volatility 95.6%; Altman Z'' 7.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Boston, MA 02109
US
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tattory John A | 0 | — | 2026-09-10 | |
| Fitzgerald Thomas A | A-Award | 185,000 | $1.78 | 2026-09-09 |
| DEFJ, LLC | C-Conversion | 1,181 | — | 2026-08-03 |
| DEFJ, LLC | C-Conversion | 202 | — | 2026-08-03 |
| DEFJ, LLC | 0 | — | 2026-07-27 |